Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/307% above fair value
$28.76−0.92 (-3.10%)
Close on Nov 19, 2026Market cap $1.72BP/E –Yield –
Agios Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Agios Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$459.02M. For fiscal 2025 it was -$472.13M. The highest annual figure on record is -$16.63M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$472.13M | – |
| FY2024 | Dec 31, 2024 | -$425.74M | – |
| FY2023 | Dec 31, 2023 | -$391.49M | – |
| FY2022 | Dec 31, 2022 | -$389.05M | – |
| FY2021 | Dec 31, 2021 | -$378.42M | – |
| FY2020 | Dec 31, 2020 | -$335.92M | – |
| FY2019 | Dec 31, 2019 | -$316.27M | – |
| FY2018 | Dec 31, 2018 | -$362.48M | – |
| FY2017 | Dec 31, 2017 | -$320.79M | – |
| FY2016 | Dec 31, 2016 | -$200.99M | – |
| FY2015 | Dec 31, 2015 | -$118.70M | – |
| FY2014 | Dec 31, 2014 | -$54.13M | – |
| FY2013 | Dec 31, 2013 | -$38.88M | – |
| FY2012 | Dec 31, 2012 | -$23.00M | – |
| FY2011 | Dec 31, 2011 | -$16.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$110.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$110.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$121.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$116.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$127.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$106.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$125.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$102.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$105.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$92.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$106.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$100.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$93.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$90.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$99.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$91.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$97.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$101.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$104.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$91.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$91.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$91.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$92.43M | – |
| Q3 FY2020 | Sep 30, 2020 | -$80.29M | – |
| Q2 FY2020 | Jun 30, 2020 | -$83.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$87.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$105.93M | – |
| Q3 FY2019 | Sep 30, 2019 | -$109.06M | – |
| Q2 FY2019 | Jun 30, 2019 | -$113.86M | – |
| Q1 FY2019 | Mar 31, 2019 | -$97.48M | – |
| Q4 FY2018 | Dec 31, 2018 | -$96.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$99.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$72.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -$94.01M | – |
| Q4 FY2017 | Dec 31, 2017 | -$90.13M | – |
| Q3 FY2017 | Sep 30, 2017 | -$79.02M | – |
| Q2 FY2017 | Jun 30, 2017 | -$84.60M | – |
| Q1 FY2017 | Mar 31, 2017 | -$67.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$57.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$63.51M | – |
See a number that looks wrong?